COST-EFFECTIVENESS ANALYSIS OF DULAGLUTIDE COMPARED WITH INSULIN GLARGINE ADD ON TO INSULIN LISPRO IN TREATMENT OF TYPE 2 DIABETES: A US THIRD-PARTY PAYER PERSPECTIVE

被引：0
|
作者：
Nili, M. [1 ]
Wu, W. [1 ]
Kumar, A. [1 ]
机构：
[1] St Johns Univ, Coll Pharm & Hlth Sci, New York, NY USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1302
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB40
引用
收藏
页码：A203 / A203
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan
    Ishii, Hitoshi
    Madin-Warburton, Matthew
    Strizek, Alena
    Thornton-Jones, Lucy
    Suzuki, Shuichi
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (05) : 488 - 496
  • [2] A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients: A Third-Party US Payer Perspective
    St Charles, Meaghan
    Lynch, Peter
    Graham, Claudia
    Minshall, Michael E.
    [J]. VALUE IN HEALTH, 2009, 12 (05) : 674 - 686
  • [3] Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective
    Permsuwan, Unchalee
    Thavorn, Kednapa
    Dilokthornsakul, Piyameth
    Saokaew, Surasak
    Chaiyakunapruk, Nathorn
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (09) : 991 - 999
  • [4] A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US
    Charles, Meaghan St.
    Minshall, Michael E.
    Pandya, Bhavik J.
    Baran, Robert W.
    Tunis, Sandra L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (06) : 1343 - 1353
  • [5] THE COST-EFFECTIVENESS OF EXENATIDE BID VERSUS INSULIN LISPRO TID AS ADD-ON THERAPY TO TITRATED INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES - AN ANALYSIS FROM THE SWEDISH HEALTH CARE PERSPECTIVE
    Gordon, J.
    McEwan, P.
    Sabale, U.
    Kartman, B.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [6] Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US
    Bruhn, David
    Martin, Alan A.
    Tavares, Ruben
    Hunt, Barnaby
    Pollock, Richard F.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 672 - 683
  • [7] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (04): : 366 - 375
  • [8] COST MINIMIZATION ANALYSIS OF INSULIN GLARGINE 300 U/ML VS GLARGINE 100 U/ML FOR THE MANAGEMENT OF TYPE 2 DIABETES FROM A PRIVATE AND PUBLIC THIRD-PARTY PAYER PERSPECTIVE IN CHILE
    Russo, M.
    Bitran, R.
    Rodriguez, J. C.
    Grassi, B.
    Aguilera, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S75 - S75
  • [9] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK
    McEwan, Phil
    Poole, Chris D.
    Tetlow, Tony
    Holmes, Paul
    Currie, Craig J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S21 - S31
  • [10] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis
    Tunis, Sandra L.
    Minshall, Michael E.
    Conner, Christopher
    McCormick, John I.
    Kapor, Jovana
    Yale, Jean-Francois
    Groleau, Danielle
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1273 - 1284
12345